Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib in previously treated advanced gastrointestinal tumors
ChiCTR2100054152Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in gastrointestinal neoplasia, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastrointestinal neoplasia
Beyond the preview
Go deeper on ChiCTR2100054152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054152.